Compare Illumina, Inc. (ILMN) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Linde PLC — how do they compare? Illumina, Inc. trades at $265 (market cap $40.43B), while Linde PLC trades at $481.06 (market cap $223.11B). The key difference: Linde PLC is far larger — about 5.5× Illumina, Inc.'s market cap, and Linde PLC pays a 1.32% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Linde PLC for 88 Days on average.
| ILMN | LIN | |
|---|---|---|
Market Cap | $40.43B | $223.11B |
Volume | 2,948,626 | 1,940,149 |
Sector | Health | Basic Materials |
52-Week High | $293.69 | $546.64 |
52-Week Low | $91.00 | $389.38 |
Typical Hold Time | 83 Days | 88 Days |
Enterprise Value | $41.79B | $246.22B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
LIN trades at $481.70, down 1.68% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings of $4.50 per share, beating estimates, and raised the lower end of its 2026 guidance. Revenue growth is steady, with a net income margin of 20.43% in 2025. Analyst consensus is overwhelmingly positive, with a $557.10 price target. Support is seen near $480, while resistance lies at $486.
Outlook remains favorable due to consistent earnings beats and a record $8.1 billion project backlog. Risks include elevated valuation multiples and margin pressures from higher capital expenditures. The stock offers a dividend yield with a $1.60 payment scheduled for September 2026. Investor sentiment is buoyed by AI-related contract wins, though competition and capex increases warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
